Cardiovascular Pharmacology: Open Access

Acknowledging Fundamental Approaches and Structural Modifications in Arteriosclerosis

Salvatore Sortino^* Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy
^*Correspondence: Salvatore Sortino, Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy, Email:

Received: 01-Nov-2023, Manuscript No. CPO-23-23888; Editor assigned: 03-Nov-2023, Pre QC No. CPO-23-23888 (PQ); Reviewed: 17-Nov-2023, QC No. CPO-23-23888; Revised: 24-Nov-2023, Manuscript No. CPO-23-23888 (R); Published: 01-Dec-2023, DOI: 10.35248/2329-6607.23.12.379

Description

Arteriosclerosis, a term encapsulating a spectrum of vascular changes, stands as a formidable force shaping the cardiovascular landscape. From the Latin words 'arteria' (artery) and 'sclerosis' (hardening), arteriosclerosis involves a progressive thickening, stiffening, and loss of elasticity in arterial walls.

Three faces of arteriosclerosis

Atherosclerosis: Atherosclerosis, the most prevalent form of arteriosclerosis, unfolds as a chronic inflammatory process within arterial walls [1]. It is characterized by the formation of atherosclerotic plaques, consisting of lipids, immune cells, and cellular debris, which accumulate in the intima—the innermost layer of the artery.

Monckeberg's medial calcific sclerosis: Monckeberg's medial calcific sclerosis, in contrast, primarily involves the calcification of the muscular middle layer (media) of arteries. This form of arteriosclerosis typically affects medium-sized arteries and is more common in older individuals.

Hyaline arteriosclerosis: Hyaline arteriosclerosis, also known as arteriolosclerosis, predominantly affects small arteries and arterioles. It is characterized by the thickening of the arteriolar walls due to the deposition of a hyaline-like substance, leading to luminal narrowing and compromised blood flow [2].

Mechanisms of action

Atherosclerosis initiates with the endothelial dysfunction—a disruption in the normally smooth lining of arterial walls. Lipids, particularly Low-Density Lipoprotein Cholesterol (LDL-C), infiltrate the damaged endothelium and undergo oxidative modifications, triggering an inflammatory response. Inflammatory cells, predominantly macrophages, engulf oxidized lipids and transform into foam cells, creating a fatty streak—the earliest visible stage of atherosclerosis [3]. Over time, a fibrous cap develops over the fatty streak, forming a mature atherosclerotic plaque. Monckeberg's medial calcific sclerosis involves the deposition of calcium in the media of arteries. The mechanisms leading to calcification are complex, involving a shift in the balance of factors that regulate vascular calcification, such as calcium-phosphate metabolism and osteogenic transformation of vascular smooth muscle cells. Hyaline arteriosclerosis primarily affects arterioles, where increased blood pressure and other factors lead to thickening and narrowing of the vessel walls. The deposition of hyaline material is a response to chronic injury, often associated with conditions like hypertension and diabetes [4].

Clinical implications

Atherosclerosis is a major contributor to Coronary Artery Disease (CAD), the leading cause of heart attacks [5]. Plaque rupture, thrombosis, and subsequent obstruction of coronary arteries can lead to myocardial infarction. The calcification seen in Monckeberg's sclerosis can impair arterial function and contribute to increased arterial stiffness. This stiffness is associated with elevated systolic blood pressure and an increased risk of adverse cardiovascular events. In hyaline arteriosclerosis, the thickening of arteriolar walls can compromise blood flow to the kidneys [6]. This form of arteriosclerosis is often implicated in hypertensive nephrosclerosis, contributing to chronic kidney disease.

Risk factors and prevention

Atherosclerosis is closely linked to modifiable risk factors, including high blood pressure, hyperlipidemia, smoking, diabetes, and obesity. Lifestyle modifications, such as a heart- healthy diet, regular exercise, and smoking cessation, play pivotal roles in prevention. Age, genetics, and family history contribute to the risk of arteriosclerosis [7]. While these factors are non- modifiable, awareness and early intervention can help manage and mitigate their impact.

Diagnosis and screening

Non-invasive imaging techniques, such as ultrasound, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), play a crucial role in diagnosing and monitoring arteriosclerosis [8]. These modalities allow for the visualization of arterial structure, plaque composition, and blood flow patterns. Blood biomarkers, including lipid profiles and inflammatory markers like C-reactive protein, aid in assessing the risk and progression of arteriosclerosis. High levels of LDL-C and inflammatory markers may indicate an increased risk of atherosclerosis.

Treatment approaches

Lifestyle interventions form the cornerstone of arteriosclerosis management. Dietary changes, regular exercise, smoking cessation, and weight management contribute to the prevention and control of arteriosclerosis [9]. Medications targeting modifiable risk factors are often prescribed. Statins, antihypertensive drugs, and antiplatelet agents are among the pharmacological interventions aimed at reducing the risk of adverse cardiovascular events. In severe cases, where arterial blockages threaten vital organs, invasive procedures such as angioplasty and stent placement may be necessary. Surgical interventions, such as Coronary Artery Bypass Grafting (CABG), are reserved for cases of extensive arterial disease [10].

Conclusion

Arteriosclerosis, in its various forms, presents a dynamic challenge to cardiovascular health. Understanding the underlying mechanisms, recognizing clinical implications, and implementing effective prevention and management strategies are essential components in the battle against this silent architect of vascular change.

References

1. Bland EF, White PD, Garland J. Congenital anomalies of the coronary arteries: Report of an unusual case associated with cardiac hypertrophy. Am Heart J. 1933;8(6):787-801.

   [Crossref] [Google Scholar]

2. Peña E, Nguyen ET, Merchant N, Dennie G. ALCAPA syndrome: Not just a pediatric disease. Radiographics. 2009;29(2):553–565.

   [Crossref] [Google Scholar]

3. Lange R, Vogt M, Hörer J, Cleuziou J, Menzel A, Holper K, et al. Long-term results of repair of anomalous origin of the left coronary artery from the pulmonary artery. Ann Thorac Surg. 2007;83(4):1463-1471.

   [Crossref] [Google Scholar]

4. Radman M, Mastropietro CW, Costello JM, Amula V, Flores S, Caudill E, et al. Intermediate Outcomes after Repair of Anomalous Left Coronary Artery From the Pulmonary Artery. Ann Thorac Surg. 2021;112(4):1307-1315.

   [Crossref] [Google Scholar]

5. Alsara O, Kalavakunta JK, Hajjar V, Alsarah A, Cho N, Dhar G. Surviving sudden cardiac death secondary to anomalous left coronary artery from the pulmonary artery: A case report and literature review. Heart Lung. 2014;43:476-480.

   [Crossref] [Google Scholar]

6. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–2371.

   [Crossref] [Google Scholar]

7. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. Mol Interv. 2006;6(2):98.

   [Crossref] [Google Scholar]

8. Mackay JH, Powell SJ, Osgathorp J, Rozario CJ. Six-year prospective audit of chest reopening after cardiac arrest. Eur J Cardiothorac Surg. 2002;22(3):421-425.

   [Crossref] [Google Scholar]

9. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism.  Circulation. 2006;113:577–582.

   [Crossref] [Google Scholar]

10. Keeling WB, Sundt T, Leacche M. Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study. Ann Thorac Surg. 2016;102:1498-1502.

    [Crossref] [Google Scholar]